

or a salt thereof.

18. A compound according to any one of claims 1 - 17, or a pharmaceutically acceptable salt thereof.

19. A compound according to any one of claims 1 – 17 in the form of a free base.

20. A pharmaceutical composition which comprises a compound or a pharmaceutically acceptable salt thereof as defined in claim 18 and one or more pharmaceutically acceptable carriers, diluents or excipients.

21. A combination product comprising a compound or a pharmaceutically acceptable salt thereof as defined in claim 18 together with one or more other therapeutically active agents.

22. A compound or a pharmaceutically acceptable salt thereof as defined in claim 18 for use in therapy.

23. A compound or a pharmaceutically acceptable salt thereof as defined in claim 18, for use in the treatment of diseases or conditions for which a bromodomain inhibitor is indicated.

24. A compound or a pharmaceutically acceptable salt thereof for use according to claim 23, wherein the disease or condition is an acute or chronic autoimmune and/or inflammatory condition.

25. A compound or a pharmaceutically acceptable salt thereof for use according to claim 23, wherein the disease or condition involves an inflammatory response to an infection with bacteria, a virus, fungi, a parasite or their toxins.

26. A compound or a pharmaceutically acceptable salt thereof for use according to claim 23, wherein the disease or condition is a viral infection.

27. A compound or a pharmaceutically acceptable salt thereof for use according to claim 23, wherein the disease or condition is cancer.

28. The use of a compound or a pharmaceutically acceptable salt thereof as defined in claim 18, in the manufacture of a medicament for the treatment of diseases or conditions for which a bromodomain inhibitor is indicated in a subject in need thereof.

29. — A method of treating diseases or conditions for which a bromodomain inhibitor is indicated in a subject in need thereof which comprises administering a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof, as defined in claim 18.

5            3029. A method of treatment The use according to claim 2928, wherein the disease or condition is an acute or chronic autoimmune and/or inflammatory condition.

             3130. A method of treatment The use according to claim 2928, wherein the disease or condition is cancer.

10

             3231. A method of treatment The use according to any one of claims 29 — 3128 - 30, wherein the subject is a human.

15

20